1
|
Tellier F, Poulet P, Ghnassia JP, Wilt M, Weitbruch D, Rodier JF. A new optical probe for the detection of the sentinel lymph node using patent blue V dye in breast cancer: A preliminary study. Mol Clin Oncol 2012; 1:143-147. [PMID: 24649137 DOI: 10.3892/mco.2012.26] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Accepted: 08/02/2012] [Indexed: 11/06/2022] Open
Abstract
The present study presents a novel near-infrared optical probe for the sentinel lymph node (SLN) detection in breast cancer patients, based on the recording of scattered photons. The aim of this study was to improve the detection of patent blue V (PBV), a dye routinely injected during clinical practice. A combined injection of the dye and radioactive colloid was used in the 24 patients enrolled in the study. The clinical results of the ex vivo detection of 70 dye-marked SLNs are reported, subsequent to the injection of various quantities of PBV (0.25-2 ml). The accuracy and success rate of an isotopic probe for the detection of radioactive colloid tracer, the eye visibility threshold of the surgeon and the use of a new optical probe were examined. The radio-labeled and dye-marked sentinel lymph nodes were all detected by the radio-isotopic probe, as opposed to the 75% detected by the eye visibility threshold of the surgeon. The optical probe detected all of the nodes, regardless of the volume of the dye injected. The relative PBV concentration computed by the probe facing SLNs with infravisible/visually undetectable dye-mark was relatively constant at 5.5±1.4 μmol/l. The optical detection of the sentinel lymph nodes using PBV and the probe presented in this study have the potential to reduce the false negative detection rate. This instrument is likely to provide surgeons with a simple diagnostic tool, without significantly changing their surgical procedures.
Collapse
Affiliation(s)
- F Tellier
- Laboratory of Imaging and Cognitive Neurosciences, UMR 7237, University of Strasbourg/CNRS
| | - P Poulet
- Laboratory of Imaging and Cognitive Neurosciences, UMR 7237, University of Strasbourg/CNRS
| | | | - M Wilt
- Departments of Pathology and
| | - D Weitbruch
- Surgical Oncology, Paul Strauss Cancer Center, 67085 Strasbourg, France
| | - J F Rodier
- Surgical Oncology, Paul Strauss Cancer Center, 67085 Strasbourg, France
| |
Collapse
|
2
|
Millon R, Muller D, Schultz I, Salvi R, Ghnassia JP, Frebourg T, Wasylyk B, Abecassis J. Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance. Oral Oncol 2001; 37:620-31. [PMID: 11590071 DOI: 10.1016/s1368-8375(00)00122-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The transforming potential of the MDM2 oncogene has been attributed to the overproduction of the protein. In order to investigate regulation of MDM2 expression in head and neck squamous cell carcinomas, we analysed MDM2 gene amplification, and mRNA and protein expression in tumour specimens from 62 patients, in cell lines, and in normal epithelium adjacent to tumours or obtained from healthy patients. Additionally, TP53-induced MDM2-P2 transcription was evaluated and compared with TP53 status. MDM2 gene amplification and mRNA over-expression is infrequent, 7 and 9%, respectively. The predominant transcript codes for full-length MDM2 protein (90kD) and the level of alternatively spliced forms is not significant. We show that only 47% of tumours exhibit MDM2 immunostaining in more than one third of the neoplastic cells, and thus more than half of the tumours display no or low levels of MDM2 protein. In contrast, MDM2 protein is always detectable in basal and parabasal cells of morphologically normal epithelium outside the invasively growing tumour, as well as in a normal uvula sample. Similarly, the total amount of MDM2 transcripts analysed by reverse transcriptase-polymerase chain reaction is reduced in tumour samples compared to normal tissues, essentially due to a decrease in P2 transcript levels. The relationship between mutated p53 status and low levels of MDM2 found in cell lines is also observed to a certain extent in primary tumour samples. Overall, there is a high frequency of TP53 mutation and under-expression of MDM2 in the head and neck tumours. Moreover, a significant association of decreased MDM2 expression is observed with advanced tumour stage and 3 years survival.
Collapse
Affiliation(s)
- R Millon
- Laboratoire de Biologie Tumorale, Centre Paul Strauss, 3 rue de la Porte de l'Hôpital, F-67085 - Strasbourg cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Coindre JM, Blanc-Vincent MP, Collin F, Mac Grogan G, Balaton A, Voigt JJ, Arnould L, Bailly C, Brifford M, Bibeau F, Fontanière B, Ghnassia JP, Guinebretière JM, Le Doussal V, Mauriac L, Merrouche Y, Sabourin JC, Sastre-Garau X, Sigal-Zafrani B, Verriele-Beurrier V, Vielh P. [Standards, options and recommendations: practice guidelines for difficult diagnosis in surgical pathology or cytopathology in cancer patients]. Bull Cancer 2001; 88:765-73. [PMID: 11578945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
CONTEXT The "Standards, Options and Recommendations" (SOR) project, started in 1993 is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French Cancer Centres and specialists from French Public Universities, General Hospitals and Private Clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients. The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. OBJECTIVES To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for difficult diagnoses in surgical pathology or cytopathology in cancer patients. METHODS Data were identified by searching Medline and using the personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to 71 independent reviewers. RESULTS The main recommendations to prevent and reduce the number of difficult diagnoses in surgical pathology or cytopathology are: 1) The development of quality insurance programs with use of written procedures in each pathology laboratory (standard). 2) The knowledge of clinical data in order to explain surgical pathology or cytopathology results (standard). 3) The availability of complementary patient informations (radiologic data . . .) can be useful to explain surgical pathology or cytopathology results (option). The main recommendations to detect lesions associated with difficult diagnosis in surgical pathology or cytopathology are: 1) Tumor types known as potential difficult diagnosis in surgical pathology or cytopathology should be reviewed by a second pathologist. 2) The systematic second reviewing for every case is expensive but has to be done when the difficulty is know (sarcoma, lymphoma . . .) by experienced pathologists. The main recommendations to solve difficult diagnosis in surgical pathology or cytopathology are: 1) Block recuts, use of special techniques (immunocytohistochemistry and molecular biology), additional data from clinicians, second opinion by a local pathologist, or new specimen can be required for establishing the diagnosis (options). 2) Outside second opinion by expert pathologist has to be considered once the other steps did not allow to establish surgical or cytopathology diagnosis (recommendations, expert agreement).
Collapse
Affiliation(s)
- J M Coindre
- Standards, Options et Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haegelé P. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7:1577-81. [PMID: 11410493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
We evaluated the predictive value of a tumor's HER-2 status for chemotherapy response in the neoadjuvant setting and the effect of anthracycline dose intensity on this predictive value. HER-2 status was evaluated by immunochemistry on microbiopsy before neoadjuvant chemotherapy (monoclonal antibody CB-11; Novocastra) in 39 patients (group A) treated with FEC50 (500 mg/m(2) 5-fluorouracil, 50 mg/m(2) epirubicin, and 500 mg/m(2) cyclophosphamide) and 40 patients (group B) treated with FEC100 (500 mg/m(2) 5-fluorouracil, 100 mg/m(2) epirubicin, and 500 mg/m(2) cyclophosphamide). All tumors were stage II or noninflammatory stage III adenocarcinoma. Overall response rate (OR) was evaluated through ultrasound and mammographic measurements. Pathological complete response was evaluated by tumor excision and axillary node resection after six cycles of chemotherapy. Patient and tumor characteristics (age, tumor size, clinical nodal status, SBR grade, hormonal receptor status, and HER-2 expression) were similar in the two groups. In univariate analyses, anthracycline dose was the only factor predictive of response (OR = 61.5% with FEC50; OR = 82.5% with FEC100; P = 0.038). When anthracycline dose was correlated with HER-2 status, an OR of 73.9% was demonstrated in HER-2- tumors (tumors without HER-2 overexpression), and an OR of 12.5% was demonstrated in HER-2+ tumors (tumors with HER-2 with overexpression) in group A. In group B, an OR of 69.5% was demonstrated in HER-2- tumors, and an OR of 100% was demonstrated in HER-2+ tumors. There was no difference in OR for HER-2- tumors treated with FEC50 or FEC100 (P = 0.74). On the other hand, erbB-2+ tumors treated with FEC100 had a significantly better OR than HER-2+ tumors treated with FEC50 (P = 0.0003). In a multivariate analysis, the most powerful predictive factor of OR was a conditional variable associating anthracycline dose with HER-2 status. Low-dose anthracycline and HER-2+ predicted a poor OR, low- or high-dose anthracycline and HER-2- predicted an intermediate OR, and high-dose anthracycline and HER-2+ predicted a high OR. Our results merit additional studies, given the possibility for choosing anthracycline dose according to a tumor's HER-2 status.
Collapse
Affiliation(s)
- T Petit
- Departments of Medical Oncology, Centre de Lutte Contre le Cancer Paul Strauss, 67085 Strasbourg Cedex, France.
| | | | | | | | | | | | | |
Collapse
|
5
|
Petit T, Ghnassia JP, Petit JC. Antitumour activity of heparin on metastatic colon cancer. Clin Oncol (R Coll Radiol) 2001; 12:249-50. [PMID: 11005694 DOI: 10.1053/clon.2000.9166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We present the case history of a 47-year-old patient with metastatic colon cancer, whose anticoagulant treatment led to a prolonged disease-free survival.
Collapse
Affiliation(s)
- T Petit
- Medical Oncology Department, Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg, France
| | | | | |
Collapse
|
6
|
Affiliation(s)
- J P Ghnassia
- Department of Pathology, Centre Regionnal de Lutte Contre Le Cancer Paul Strauss, Strasbourg, France.
| | | | | |
Collapse
|
7
|
Rodier JF, Routiot T, Mignotte H, Janser JC, Bremond A, David E, Barlier C, Ghnassia JP, Treilleux I, Chassagne C, Velten M. Lymphatic mapping and sentinel node biopsy of operable breast cancer. World J Surg 2000; 24:1220-5; discussion 1225-6. [PMID: 11071466 DOI: 10.1007/s002680010240] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The aim of this study was to evaluate the reliability and accuracy of sentinel node biopsy for invasive breast cancer and the predictability of axillary node status. Between January 1996 and June 1997 a total of 73 patients underwent patent blue dye lymphatic mapping and sentinel node biopsy followed by standard (level I and II) axillary node dissection (one bilateral procedure). The sentinel node was identified in 82.4% (61/74) of the cases and was predictive of axillary status in 96.7% (59/61). The false-negative rate of the procedure was 8.0% (2/25). The sentinel node was involved in 37.7% (23/61) and was the only one invaded in 30.4% (7/23). The sensitivity of the procedure was 92% (CI95% 74-99%) and its specificity 100%. It is currently considered to be an attractive new procedure undergoing evaluation in prospective controlled trials. This study confirmed the reliability and reproducibility of intraoperative lymphatic mapping and sentinel node biopsy. This is the first step toward a new era of minimally invasive axillary surgery for breast cancer.
Collapse
Affiliation(s)
- J F Rodier
- Department of Surgical Oncology, Paul Strauss Comprehensive Cancer Center, Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Petit T, Ghnassia JP, Petit JC. Antitumour Activity of Heparin on Metastatic Colon Cancer. Clin Oncol (R Coll Radiol) 2000. [DOI: 10.1007/s001740070048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Lagrange JL, Ramaioli A, Chateau MC, Marchal C, Resbeut M, Richaud P, Lagarde P, Rambert P, Tortechaux J, Seng SH, de la Fontan B, Reme-Saumon M, Bof J, Ghnassia JP, Coindre JM. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Fédération Nationale des Centres de Lutte Contre le Cancer. Radiology 2000; 216:197-205. [PMID: 10887248 DOI: 10.1148/radiology.216.1.r00jl02197] [Citation(s) in RCA: 155] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
PURPOSE To evaluate the best strategy for treatment of sarcoma that occurs after radiation therapy. MATERIALS AND METHODS Records were retrospectively reviewed for 80 patients with a confirmed histologic diagnosis of sarcoma that occurred after radiation therapy performed during 1975-1995. The patients were treated for breast cancer (n = 33, 42%), non-Hodgkin lymphoma (n = 9, 11%), cervical cancer (n = 9, 11%), benign lesions (n = 4, 5%), or other tumors (n = 25, 31%). Sarcoma occurred after a mean latency of 12 years (range, 3-64 years), with most (70%) developing in the soft tissue. Treatment included surgery (28 patients), surgery and chemotherapy (18 patients), chemotherapy only (15 patients), and radiation therapy (14 patients). RESULTS By the end of the study, 51 patients were dead, including 46 due to sarcoma. Median survival was 23 months. Overall survival rates at 2 and 5 years, respectively, were 69% and 39% for patients treated with surgery, 10% and 0% for those treated with chemotherapy, and 52% and 35% for those treated with surgery and chemotherapy (P =.001). The 2- and 5-year rates for survival without recurrence were 54% and 32%, respectively. CONCLUSION The results confirm the beneficial effect of surgery. Further study is needed to explore the roles of combined treatments.
Collapse
Affiliation(s)
- J L Lagrange
- Radiation Oncology Department, Centre Antoine Lacassagne, 33 avenue de Valombrose, 06189 Nice 2, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Rodier JF, Janser JC, Routiot T, David E, Ott G, Schneegans O, Ghnassia JP. Sentinel node biopsy in vulvar malignancies: a preliminary feasibility study. Oncol Rep 1999; 6:1249-52. [PMID: 10523690 DOI: 10.3892/or.6.6.1249] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Sentinel lymph node biopsies (SLNB) were investigated in 8 cases (6 squamous cell carcinomas, 2 melanomas) of vulvar malignancy. The sentinel node was detected by patent blue dye injection (1 case), pre operative lymphoscintigraphy with intra-operative gamma hand-held probe (2 cases), and combined techniques (5 cases). The procedure was successful in all cases but one (1 invasive squamous cell carcinoma) in which there was medial groin recurrence at 6 months. Nodal invasion was observed in only one case and was confined to the sentinel node. No specific morbidity related to the SLNB procedure occurred. SLNB appears to be a feasible and promising technique, however, requiring further evaluation before being considered as a reliable method to spare inguinofemoral lymphadenectomy in early-stage patients free of sentinel node metastasis, or to be substituted in screening elderly clinically node-negative females.
Collapse
Affiliation(s)
- J F Rodier
- Department of Surgical Oncology, Paul Strauss Cancer Center, 67085 Strasbourg Cedex, France
| | | | | | | | | | | | | |
Collapse
|
11
|
Affiliation(s)
- J P Ghnassia
- Centre Regional de Lutte Contre le Cancer Paul Strauss, Strasbourg, France.
| | | | | | | |
Collapse
|
12
|
Rodier JF, Routiot T, Mignotte H, Janser JC, Bremond A, Barlier C, Ghnassia JP, Treilleux I, Chassagne C, Velten M. [Identification of axillary sentinel node by lymphotropic dye in breast cancer. Feasibility study apropos of 128 cases]. Chirurgie 1998; 123:239-46. [PMID: 9752514 DOI: 10.1016/s0001-4001(98)80115-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
AIM OF THE STUDY The goal of this study was to evaluate the technical feasibility of sentinel node biopsy in breast cancer and its predictivity of axillary node status. PATIENTS AND METHODS Between January 1996 and June 1997, 128 patients with invasive breast carcinomas, referred to the Cancer Center of Strasbourg and Lyon (France), underwent lymphatic mapping (Patent Blue dye) and sentinel node biopsy followed by axillary clearance (Berg's level I to II). RESULTS Sentinel node was identified in 76.5% of cases and was predictive of axillary status in 94.9% of cases. The false negative rate of the procedure was 5.1%. Sentinel lymph node was involved in 43.9% of cases and it was the only one involved in 30.2% of cases. The sensitivity of the procedure was 94% (CI: 95% = [88%-98%]) and its specificity 100%. CONCLUSION Actually considered as new attractive procedure under ongoing evaluation in prospective controlled trials, this study confirms the feasibility and reproductibility of lymphatic mapping and sentinel node biopsy, first stage before entering a new era of minimally invasive axillary surgery in breast cancer.
Collapse
Affiliation(s)
- J F Rodier
- Centre régional de lutte contre le cancer Paul-Strauss, Strasbourg, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Ghnassia JP. [Proliferating cell nuclear antigen (PCNA)]. Ann Pathol 1996; 16:241-6. [PMID: 9172611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- J P Ghnassia
- Service d'Anatomie Pathologique, Centre Régional de Lutte contre te Cancer Paul Strauss, Strasbourg
| |
Collapse
|
15
|
Barsotti P, Schloegel M, Ollier JC, Ghnassia JP, Potet F, Adloff M. [Cystic dystrophy on an aberrant duodenal pancreas. Apropos of a case]. J Chir (Paris) 1995; 132:503-5. [PMID: 8815063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Cystic dystrophy of the aberrant pancreas is a rare poorly understood condition which is difficult to diagnose and treat. The primary clinical signs are epigastralgia associated with poor general health and complications due to stenosis of the duodenum. Endoscopy gives the most information on tissue lesions and cystic formations in the duodenal mucosa. Although the condition is benign, and due to the lack of sufficient history in endoscopically treated cases, cystic dystrophy of the aberrant duodenal pancreas appears to require duodenopancreatectomy.
Collapse
|
16
|
Oswald P, Filippi de la Palavesa MM, Uhl G, Ghnassia JP, Doffoel M, Dietemann JL. [Hepatosplenic silicosis]. J Radiol 1995; 76:513-6. [PMID: 7473390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
A case of hepatosplenic silicosis complicating a pulmonary silicosis is reported. Numerous calcified splenic nodules seen with conventional radiology, ultrasound or computed tomography, hepatic microcalcifications and "egg shell" abdominal lymph nodes best seen with computed tomography represent the radiologic signs. However, hepatosplenic silicosis can only be confirmed by pathological examination of liver biopsies showing birefringent particles within hyalinized nodules.
Collapse
Affiliation(s)
- P Oswald
- Service de Radiologie B, Hôpital Central, Hôpitaux Universitaires de Strasbourg
| | | | | | | | | | | |
Collapse
|
17
|
Rodier JF, Ghnassia JP, Janser JC. [Intrathyroid metastasis from cancer of the breast]. J Chir (Paris) 1995; 132:51-2. [PMID: 7730428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
18
|
Rodier JF, Ghnassia JP, Janser JC, Delahaye JF, Methlin A, Klein T. [Non-Hodgkin's malignant lymphoma of the cervix uteri]. J Chir (Paris) 1993; 130:554-555. [PMID: 7512977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
19
|
Gasser B, Mauss Y, Ghnassia JP, Favre R, Kohler M, Yu O, Vonesch JL. A quantitative study of normal nephrogenesis in the human fetus: its implication in the natural history of kidney changes due to low obstructive uropathies. Fetal Diagn Ther 1993; 8:371-84. [PMID: 8286028 DOI: 10.1159/000263855] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
An evaluation of nephrogenesis according to fetal age was performed by quantifying the state of the nephrogenic blastema (NB) and the number of glomeruli (GN) on frontal renal sections in 99 control fetuses (gestational age ranging from 9 to 40 weeks) and in 17 aborted fetuses with low urinary tract obstruction (gestational age ranging from 14 to 36 weeks). In the control group, GN increases slowly from the 10th to the 18th week, then abruptly from the 18th to the 32nd week, reaching an upper limit with NB disappearance by the 32nd week. In the uropathy group, the renal changes show a wide range of severity clearly accounted for by the impairment of both NB and GN. The dysplastic effect of urinary backpressure is the more consistent pathogeny with the spectrum of observed renal changes. It is likely, from GN used as a time-dependent marker of renal development, that the most severe dysplasia is the result of early obstruction with abnormal disappearance of NB and subsequent arrest of nephrogenesis.
Collapse
Affiliation(s)
- B Gasser
- Institut de Pathologie, URA 1173 du CNRS, Faculté de Médecine ULP, Strasbourg, France
| | | | | | | | | | | | | |
Collapse
|
20
|
Saussine C, Jacqmin D, Babin-Boilletot A, Ghnassia JP, Bollack C. [Rhabdomyosarcoma of the prostate. Diagnostic course and current therapy. Report of a case of a 17-year-old boy]. Prog Urol 1992; 2:913-8. [PMID: 1302120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The authors report a case of rhabdomyosarcoma in a 17 year old boy which recurred after combination chemotherapy and radical prostatectomy, followed by death of the patient due to haematological complications of second-line chemotherapy. The diagnosis of these rhabdomyosarcomas is facilitated by the various immunohistochemical stains now available. Chemotherapy is undeniably effective and, combined with surgery and radiotherapy, ensures a 5-year survival of 47% to 93% depending on the stage. The first-line chemotherapy avoids the need for radiotherapy in the early stages and allows less mutilating surgical procedures, while maintaining the survival rate.
Collapse
Affiliation(s)
- C Saussine
- Service de Chirurgie Urologique, C.H.U. Strasbourg
| | | | | | | | | |
Collapse
|
21
|
Luton JP, Ghnassia JP, Bricaire H. [Medical treatment and Cushing's disease]. Sem Hop 1977; 53:1476-9. [PMID: 197640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The drugs proposed are considered according to their site of action. Synthetic anti-cortisol drugs (Op'DDD in particular and aminoglutethimide) appear to be the drugs of choice at present. They act on the adrenals, but research is now being carried out on drugs which act on ACTH secretion, E.g; cyproheptadine and bromocriptine.
Collapse
|
22
|
Suhler A, Blanchard J, Benkoel L, Ghnassia JP. [Leydig cell testicular tumour with an endocrine syndrome. Clinical, biological, ultra-structural and histo-enzymatic study (author's transl)]. J Urol Nephrol (Paris) 1976; 82:201-17. [PMID: 1011340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
With respect to a particularly demonstrative case of Leydig cell tumour with gynaecomastia in a 40 year old man, the authors review the current data in the literature concerning the clinical and biological features and treatment of this tumour. They pay particular attention to the classical anatomo-pathological features, the ultra-structure and the ultrastructural and histo-enzymatic appearances.
Collapse
|
23
|
Bourgeon R, Ghnassia JP, Audoly P, Navarro B, Kermarec J. [Islet cell adenoma and arteriography]. J Chir (Paris) 1972; 103:509-14. [PMID: 4347254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
24
|
Mauvais-Jarvis P, Ghnassia JP, Dolais J, Rosselin G. [Action of clomiphene citrate on plasma gonadotropin level (H-FSH and H-LH)]. Presse Med (1893) 1969; 77:1759-62. [PMID: 5364162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
25
|
Ghnassia JP, de Gennes JL. [Pseudohypothyroidism produced by hypercholesterolemic xanthomatosis associated with Gougerot-Sjogren syndrome and exogenous iodine overloading]. Rev Fr Endocrinol Clin 1969; 10:233-6. [PMID: 5809101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
26
|
Ghnassia JP, Mauvais-Jarvis P. [Induction of ovulation by clomiphene (73 treated cycles)]. Gynecol Obstet (Paris) 1969; 68:41-9. [PMID: 5404671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
27
|
Mauvais-Jarvis P, Ghnassia JP. [Recent data on the artificial induction of ovulation. II. Clomiphene]. Presse Med (1893) 1967; 75:2555-9. [PMID: 4864699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
28
|
Mauvais-Jarvis P, Ghnassia JP. [Recent data on artificial induction of ovulation. I. Human gonadotropins]. Presse Med (1893) 1967; 75:2449-54. [PMID: 4864447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
29
|
Jayle GE, Tassy AF, Ghnassia JP. [Prognostic value of the electroretinogram in fresh, severe ocular injuries with an invisible ocular fundus]. Bull Soc Ophtalmol Fr 1967; 67:685-90. [PMID: 5598095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
30
|
Ghnassia JP, Dray F, Mowzovicz I, Sebaoun J, Delzant G, Thervet F. [An investigation of Leydig cell function in the feminizing testicle]. ANNALES D'ENDOCRINOLOGIE 1967; 28:368-74. [PMID: 4867198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
31
|
Decourt J, Michard JP, Mauvais-Jarvis P, Ghnassia JP. [The endocrine disorders of psychoneurotic oligophagic cachexia. (Mental anorexia, anorexia nervosa)]. Bull Mem Soc Med Hop Paris 1965; 116:1103-22. [PMID: 5840749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|